Phase II Study of Abiraterone Acetate Plus Prednisone in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Demonstrating Radiographic Flare Discordant With Serologic Measures of Response

PURPOSE: Abiraterone is an oral inhibitor of CYP17, essential for androgen biosynthesis. This multicenter study assessed its efficacy in patients with CRPC without prior exposure to chemotherapy or CYP17 targeted therapy, and assessed the frequency of interpretation of bone scans discordant with PSA...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Ryan, Charles J., Shah, Shreya, Efstathiou, Eleni, Smith, Matthew R., Taplin, Mary-Ellen, Bubley, Glenn J., Logothetis, Christopher J., Kheoh, Thian, Kilian, Christine, Haqq, Chris, Molina, Arturo, Small, Eric J.
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3657705/
https://ncbi.nlm.nih.gov/pubmed/21632851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-0815
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki